Answers are grounded in this paper and cite their sources.
Pembrolizumab is a humanized antibody that targets the programmed cell death-1 (PD-1) receptor. It is currently approved by the US Food and Drug Administration for patients with advanced melanoma and metastatic non–small cell lung cancer. As an immune checkpoint inhibitor, pembrolizumab augments a patient's immune system against an underlying malignancy.
No takes yet. Share an insight, caveat, or question.
Cotliar et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: